Hybrid Liposome-MSN System with Co-Delivering Potential Effective Against Multidrug-Resistant Tumor Targets in Mice Model
International Journal of Nanomedicine · 2024-09 · Volume 19 · 8949-8970
DOI: 10.2147/ijn.s472276 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2024-09. Verfasst von Yanan Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Biological Engineering, Henan University of Technology, Zhengzhou, People's Republic of China. Hauptthemen laut MEDLINE: Doxorubicin, Liposomes, Drug Resistance, Neoplasm, RNA, Small Interfering. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Introduction
RNA interference (RNAi) stands as a widely employed gene interference technology, with small interfering RNA (siRNA) emerging as a promising tool for cancer treatment. However, the inherent limitations of siRNA, such as easy degradation and low bioavailability, hamper its efficacy in cancer therapy. To address these challenges, this study focused on the development of a nanocarrier system (HLM-N@DOX/R) capable of delivering both siRNA and doxorubicin for the treatment of breast cancer.
Methods
The study involved a comprehensive investigation into various characteristics of the nanocarrier, including shape, diameter, Fourier transform infrared (FT-IR) spectroscopy, X-ray photoelectron spectroscopy (XPS), encapsulation efficiency, and drug loading. Subsequently, in vitro and in vivo studies were conducted on cytotoxicity, cellular uptake, cellular immunofluorescence, lysosome escape, and mouse tumor models to evaluate the efficacy of the nanocarrier in reversing tumor multidrug resistance and anti-tumor effects.
Results
The results showed that HLM-N@DOX/R had a high encapsulation efficiency and drug loading capacity, and exhibited pH/redox dual responsive drug release characteristics. In vitro and in vivo studies showed that HLM-N@DOX/R inhibited the expression of P-gp by 80%, inhibited MDR tumor growth by 71% and eliminated P protein mediated multidrug resistance.
Conclusion
In summary, HLM-N holds tremendous potential as an effective and targeted co-delivery system for DOX and P-gp siRNA, offering a promising strategy for overcoming MDR in breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biological Engineering, Henan University of Technology, Zhengzhou, People's Republic of China.
- Key Laboratory of Functional Molecules for Biomedical Research, Zhengzhou, People's Republic of China.
Zitieren
APA
Yang, Y., Yang, S., Zhang, B., Wang, J., Meng, D., Cui, L., & Zhang, L. (2024). Hybrid Liposome-MSN System with Co-Delivering Potential Effective Against Multidrug-Resistant Tumor Targets in Mice Model. International Journal of Nanomedicine, Volume 19, 8949-8970. https://doi.org/10.2147/ijn.s472276
Vancouver
Yang Y, Yang S, Zhang B, Wang J, Meng D, Cui L, et al. Hybrid Liposome-MSN System with Co-Delivering Potential Effective Against Multidrug-Resistant Tumor Targets in Mice Model. International Journal of Nanomedicine. 2024;Volume 19:8949-8970. doi:10.2147/ijn.s472276
BibTeX
@article{Yang2024,
author = {Yang, Yanan and Yang, Shuoye and Zhang, Beibei and Wang, Jinpeng and Meng, Di and Cui, Lan and Zhang, Lu},
title = {Hybrid Liposome-MSN System with Co-Delivering Potential Effective Against Multidrug-Resistant Tumor Targets in Mice Model},
journal = {International Journal of Nanomedicine},
year = {2024},
volume = {Volume 19},
pages = {8949--8970},
doi = {10.2147/ijn.s472276}
}
EUVIMED